ReviewCardiovascular diagnosis and therapy2021
Overview of the socio-economic consequences of heart failure.
Review in Cardiovascular diagnosis and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Cost of Chronic Heart Failure Among Adult Europeans-A Systematic Literature Review.PharmacoEconomics - open · 2026Pooled it
- Evaluation of the efficiency of at least 24-hour observation of transition to oral diuretic therapy before discharge on 30-day outcomes in acute heart failure patients: a comparative systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Heart failure: assessment of the global economic burden.European heart journal · 2025Pooled it
- Economic Evaluations of Digital Health Interventions for Patients With Heart Failure: Systematic Review.Journal of medical Internet research · 2024Pooled it
- Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Trial
- Comparative Effectiveness of Non-Pharmacological Interventions for Reducing Heart Failure-Related Unplanned Readmissions: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2026Review
- Article
- Prognostic value of the hemoglobin-to-red cell distribution width ratio (HRR) in predicting mortality and rehospitalization in patients with chronic heart failure.BMC research notes · 2026Article
- Economic impact of heart failure in Brazil.Journal of global health · 2026Article
- AI task-shifting for echocardiographic LVEF assessment in Singapore: an economic evaluation.ESC heart failure · 2026Article
- The Narrative Review: Advancements in Heart Failure Diagnosis and Management using Artificial Intelligence: A New Era of Patient Care.Current cardiology reviews · 2026Review
- Prolonged length of hospital stay and its associated factors among patients admitted with heart failure: a cross-sectional study in Dar Es Salaam, Tanzania.BMC cardiovascular disorders · 2025Article
- Wearable technologies to predict and prevent and heart failure hospitalizations: a systematic review.European heart journal. Digital health · 2025Review
- Point-of-care ultrasound can make the difference in patients with heart failure at primary care.Family practice · 2025Article
- Nonlinear association between visceral fat metabolism score and heart failure: insights from LightGBM modeling and SHAP-Driven feature interpretation in NHANES.BMC medical informatics and decision making · 2025Article
- Worsening heart failure: progress, pitfalls, and perspectives.Heart failure reviews · 2025Review
- Utilization and dose optimization of beta-blockers in chronic heart failure therapy: a mixed-methods study.BMC cardiovascular disorders · 2025Article
- Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years.European heart journal · 2025Article
- Gut microbiota-related modulation of immune mechanisms in post-infarction remodelling and heart failure.ESC heart failure · 2025Review
- Artificial intelligence in heart failure - a comprehensive literature review.Cardiology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a frequent cause of morbidity and mortality worldwide. The prevalence of HF increases, and in high-income countries, 1-2% of total healthcare expenditure is spent on HF. This article gives an overview on the impact of HF on health-related quality of life (HRQoL) and the economic burden of HF. Those suffering from HF are associated with a substantial decrease of HRQoL compared to individuals with most other chronic diseases and to individuals without HF. Therapeutic approaches, which decrease risk factors and lead to an improvement of the clinical status of patients, have a positive effect on HRQoL of the patients. Hospitalization rates have been shown to be correlated with disease severity, mortality, and HRQoL. Inpatient treatments of HF patients are cost intensive and the most important component for the economic burden of HF, responsible for at least half of direct cost. Prevention strategies, diagnostic and therapeutic approaches should focus on avoiding need for hospitalizations, and in particular, readmissions. Outpatient care including medication represents the second largest cost component. The cost of HF varies from less than 1,000 USD per patient in low-income countries to between 5,000 and 15,000 EUR in Europe, and between 17,000 and 30,000 USD in the US. There is a lack of study results on indirect costs. All study results on the socio-economic burden of HF clearly underscore the public health relevance of HF, showing a large economic burden for healthcare systems all over the world and a considerable impact on patients' HRQoL. The results on HRQoL are relatively homogeneous, but there are large differences across countries in respect of the economic burden they have to bear. Despite the large number of studies on the socio-economic consequences of HF further research is necessary, especially on indirect cost and for low- and middle-income countries. Future studies would benefit from a greater standardization of methods and presentation of results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.